Q3 2024 Ajanta Pharma Ltd Earnings Call Transcript
Ladies and gentlmen, good day and welcome to Ajanta Pharma Q3 FY24 earnings conference call. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Yogesh Agrawal, Managing Director of Ajanta Pharma Limited. Thank you and over to you, sir.
Thank you. Good evening, everyone, and welcome to this earnings call. With me, I have Mr. Rajesh Agrawal, our Joint Managing Director; Mr. Arvind Agrawal, our CFO; and Mr. Rajeev Agrawal, our EVP, Finance and Investor Relations.
I hope that the results are already there with you. We will take you through the business-wise performance for the Q3 and nine months of the current year, along with the comparison of previous year same period.
I am pleased to inform you that the Board of Directors have approved the second interim dividend for the current year. The share of INR2 face value will receive a dividend of INR26 amounting to the dividend amount of INR327 crore. In
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |